Axsome Therapeutics Reports Third Quarter 2024 Financial

2 days ago · NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of …

$100
OFF

Axsome Therapeutics (AXSM) Q3 2024 Earnings Call Transcript

2 weeks from now

2 days ago · The third quarter was another strong quarter and represented a notable milestone as we delivered quarterly product revenue in excess of $100 million for the first time. This …

nasdaq.com

$104
OFF

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q3 2024 Earnings Call …

2 weeks from now

Today, I will share our third quarter financial results and provide some financial guidance. We delivered yet another robust quarter and recorded total net product revenue of $104.8 million, …

msn.com

81%
OFF

Axsome Therapeutics Reports Third Quarter 2024 Financial Results …

2 weeks from now

2 days ago · Axsome Therapeutics (AXSM) reported strong Q3 2024 financial results with total net product revenue of $104.8 million, up 81% year-over-year. Auvelity sales reached $80.4 …

stocktitan.net

$18
OFF

Leap Therapeutics Reports Third Quarter 2024 Financial Results

2 weeks from now

1 day ago · Selected Third Quarter 2024 Financial Results Net Loss was $18.2 million for the third quarter 2024, compared to $13.7 million for the same period in 2023. The increase was …

prnewswire.com

$34
OFF

Kyverna Therapeutics Provides Business Update And Reports Third …

2 weeks from now

1 day ago · For the quarter ended September 30, 2024, the company reported a net loss of $34.3 million, or a net loss per common share of $0.80, compared to a net loss of $15.5 million, or a …

prnewswire.com

FAQs about Axsome Therapeutics Reports Third Quarter 2024 Financial Coupon?

What did Axsome Therapeutics do in Q3 2024?

NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced financial results for the third quarter of 2024 and provided a general business update. ...

What time does Axsome Therapeutics (axsm) call a conference call?

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ET Company Participants Darren Opland - Director, Corporate Communications Herriot Tabuteau - CEO Nick Pizzie - CFO Ari Maizel - EVP and Head, Commercial Mark Jacobson - Chief Operating Officer Conference Call Participants ...

Who is Axsome Therapeutics?

Axsome Therapeutics is a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) conditions. We deliver scientific breakthroughs by identifying critical gaps in care and develop differentiated products with a focus on novel mechanisms of action that enable meaningful advancements in patient outcomes. ...

How has Axsome performed in 2024?

In closing, we have made significant progress in 2024, our second full year as a commercial company in a firmly established Axsome as a trusted partner for providers, patients, and payers, providing a solid foundation for continued commercial performance for Auvelity, and Sunosi, as well as future product launches. ...

When is NDA submission for axs-14 for fibromyalgia expected?

NDA submission for AXS-14 for the management of fibromyalgia anticipated November 2024 Company to host conference call today at 8:00 AM Eastern ...

How much money does Axsome have in SG&A?

SG&A expenses increased to $95.6 million, linked to commercial strategies and sales force expansions. Axsome manages $327 million in cash reserves, which it asserts will suffice to reach future cash flow positivity. Other than its discussion of cash reserves, Axsome offered no specific guidance in this latest report. ...